Valuation: ADC Therapeutics SA

Market Cap 145M 127M 119M 109M 205M 13.91B 207M 1.41B 551M 6.87B 544M 533M 23.73B P/E 2026 *
-1.33x
P/E 2027 * -1.72x
Enterprise Value 145M 127M 119M 109M 205M 13.91B 207M 1.41B 551M 6.87B 544M 533M 23.73B EV / Sales 2026 *
1.79x
EV / Sales 2027 * 1.17x
Free-Float
83.84%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: ADC Therapeutics SA

1 day-0.87%
1 week-9.52%
Current month+6.54%
1 month+11.76%
3 months-69.68%
6 months-68.25%
Current year-67.71%
1 week 1.12
Extreme 1.12
1.28
1 month 1
Extreme 1
1.46
Current year 0.78
Extreme 0.7796
4.98
1 year 0.78
Extreme 0.7796
4.98
3 years 0.36
Extreme 0.3599
6.04
5 years 0.36
Extreme 0.3599
32
10 years 0.36
Extreme 0.3599
56.59
Manager TitleAgeSince
Chief Executive Officer 53 09/05/2022
Director of Finance/CFO 54 19/12/2022
Chief Tech/Sci/R&D Officer 52 01/10/2024
Director TitleAgeSince
Director/Board Member 67 01/06/2019
Director/Board Member 53 01/06/2018
Chairman 59 01/03/2020
Date Insider Type Main position Quantity % Market Cap.
30/6/26 Free

Chief Executive Officer

675,000 0.5307%
30/6/26 Free

Chief Technology Officer

213,900 0.1682%
30/6/26 Free

Chief Financial Officer

203,700 0.1602%
Change 5-day change 1-year change 3-year change Capi.($)
-0.87%-9.52%-65.24%-8.06% 146M
-1.82%+4.80%+56.71%+68.36% 57.28B
-0.27%+0.35%+40.26%+79.88% 54.99B
-2.05%-2.14%+0.75%+413.38% 23.18B
+1.97%-1.16%-21.00%-13.25% 22.59B
+0.16%-0.26%+21.00%-10.58% 20.46B
+1.57%+3.30%+28.01%-29.07% 17.56B
-1.85%-1.47%+31.94%+544.91% 15.67B
+5.29%+1.70%+185.09%+333.94% 14.46B
+0.79%+0.50%+22.39%+184.74% 13.92B
Average +0.29%-0.13%+29.99%+156.43% 24.02B
Weighted average by Cap. -0.14%+1.52%+39.15%+136.52%

Financials

2026 *2027 *
Net sales 80.89M 71.11M 66.2M 60.79M 114M 7.76B 116M 787M 307M 3.83B 304M 297M 13.24B 124M 109M 101M 93.05M 175M 11.87B 177M 1.2B 470M 5.86B 465M 455M 20.26B
Net income -136M -120M -111M -102M -192M -13.05B -195M -1.32B -517M -6.45B -511M -500M -22.28B -117M -103M -96M -88.17M -166M -11.25B -168M -1.14B -446M -5.56B -440M -431M -19.2B
Net Debt - -
Logo ADC Therapeutics SA
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Employees
191
Date Price Change Volume
27/07/26 USD 1.140 -0.87% 787,713
24/07/26 USD 1.150 -5.74% 725,745
23/07/26 USD 1.220 -1.61% 579,880
22/07/26 USD 1.240 -2.36% 787,166
21/07/26 USD 1.270 +0.79% 861,184
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.140USD
Average target price
5.000USD
Spread / Average Target
+338.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADCT Stock